Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy

@article{Coffin2011HepatitisBV,
  title={Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy},
  author={Carla S. Coffin and Patricia M. Mulrooney-Cousins and Guido van Marle and John P. Roberts and Tomasz I. Michalak and Norah A. Terrault},
  journal={Liver Transplantation},
  year={2011},
  volume={17}
}
The characterization of hepatitis B virus (HBV) quasispecies in different compartments in liver transplant (LT) recipients may be helpful in optimizing prophylaxis regimens. The aims of this study were to evaluate liver, peripheral blood mononuclear cells (PBMC), and plasma samples for HBV and to compare the quasispecies in hepatic and extrahepatic sites in LT recipients on long‐term prophylaxis. For 12 patients followed for up to 15 years post‐LT, liver, plasma, and PBMC samples [all HBV DNA… 
Compartmental HBV evolution and replication in liver and extrahepatic sites after nucleos/tide analogue therapy in chronic hepatitis B carriers.
  • Shan Gao, Z. Duan, C. Coffin
  • Biology, Medicine
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2017
The detection of (total and ccc) HBV DNA in liver transplant recipients with hepatitis B vaccine against HBV reinfection
TLDR
The lack of HBV total DNA and ccc DNA both in PBMCs and the liver in liver transplant recipients who received hepatitis B vaccination to prevent HBV reinfection should be a prerequisite for the withdrawal of HBIG and/or antiviral agents.
Deep sequencing shows low‐level oncogenic hepatitis B virus variants persists post–liver transplant despite potent anti‐HBV prophylaxis
TLDR
Although HBV control and cccDNA transcriptional silencing may occur despite immunosuppression, complete virological eradication does not occur in LT recipients with a history of HBV‐related end‐stage liver disease.
Withdrawal of posttransplant hepatitis B virus prophylaxis: A blind test
  • B. Roche, D. Samuel
  • Medicine, Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2016
TLDR
The ability to improve the efficacy of HBV prophylaxis is limited with possible improvement including reduction of costs and more convenient regimens, however, the use of IV HBIG has limitations.
Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.
Prevention of Post-transplant HBV
TLDR
A more cautious approach is necessary for patients with high pre-transplant HBV replication, patients with HIV or hepatitis D virus coinfection or preexisting HBV drug resistance, those with a high risk of hepatocellular carcinoma recurrence, and those at risk of noncompliance with antiviral therapy.
Individualizing hepatitis B infection prophylaxis in liver transplant recipients.
Compartmentalization of hepatitis B virus: Looking beyond the liver.
  • S. Datta
  • Biology, Medicine
    World journal of hepatology
  • 2015
TLDR
The gaps that are required to be filled to properly understand the biological and clinical relevance of extrahepatic tropism of HBV are delineated.
Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin
Abstract Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates, such as entecavir or tenofovir, suppress hepatitis B virus (HBV) replication, improve liver function in
Hepatitis B virus lymphotropism: emerging details and challenges
TLDR
HBV infection in extrahepatic sites (i.e., PBMC) is implicated in multiple facets of HBV pathogenesis such as persistence, viral evolution and vertical transmission.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy
TLDR
Despite apparent HBV suppression, the liver continues to support HBV replication and extrahepatic HBV can be detected, suggesting PBMC may be a sanctuary for wt virus during antiviral therapy, while the liver harbours more drug‐resistant viruses.
Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation
TLDR
The findings suggest that occult HBV reinfection occurs in most HBV patients after OLT and continued administration of appropriate prophylactic therapy is important in preventing overt HBV recurrence.
Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis
  • Cindy K Cheung, C. Lo, K. Man, G. Lau
  • Medicine, Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2010
TLDR
An occult HBV infection after liver transplantation can originate from both the donor and recipient despite prolonged nucleoside analogue prophylaxis, and HBV infections of both donor and recipients origins are revealed.
Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence
  • A. Marzano, S. Gaia, M. Rizzetto
  • Medicine, Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2005
TLDR
Analysis of the correlation between the viral load, tested with a single amplified assay, at the time of liver transplantation, and the risk of hepatitis B recurrence in 177 HBV carriers who underwent transplantation in a single center from 1990 to 2002 indicates the best prophylaxis strategy.
Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model.
TLDR
OLT provides a model for studying the interaction between HBV, PBMC, and the liver, and demonstrates persistent infection of PBMC in the absence of liver HBV.
HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis
TLDR
Although there were only a few cases of HBV recurrence after 5 years, HBV DNA remained present in 45% of patients at 10 years, and the efficacy of long‐term HBIG immunoprophylaxis is confirmed.
Combination Therapy in Liver Transplant Recipients with Hepatitis B Virus Without Hepatitis B Immune Globulin
TLDR
Safety and short term results show nucleoside therapy is adequate at preventing HBV viral recurrence and the economic benefit for ADV and LAM vastly outweighed the HBIg and L AM group.
Liver transplantation in European patients with the hepatitis B surface antigen.
TLDR
In this retrospective study of HBsAg-positive patients, liver transplantation had better results in those who had fulminant hepatitis or delta virus superinfection and reduced mortality.
...
1
2
3
4
...